{"id":"W4281627373","doi":"10.1016/s0140-6736(22)00467-6","title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","year":2022,"lang":"en","type":"article","venue":"The Lancet","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":387,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; University of Alberta; University of Calgary","funders":"UCB Pharma; Pfizer Japan; Samsung; Genentech; Norgine; Sun Pharma; Eli Lilly and Company; Ono Pharmaceutical; Daiichi-Sankyo; Mitsubishi Tanabe Pharma Corporation; Celltrion; Mylan; Celgene; Pfizer; Biogen; EA Pharma Co., Ltd.; Gilead Sciences; AbbVie; Kyorin Pharmaceutical; Sanofi; Tillotts Pharma; Allergan; AstraZeneca; Seres Therapeutics; Nichi-Iko Pharmaceutical; Amgen","keywords":"Medicine; Placebo; Crohn's disease; Internal medicine; Population; Clinical trial; Randomized controlled trial; Disease; Physical therapy; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001038038,0.0001218236,0.0001718959,0.00001156471,0.0004621602,0.000040265,0.0002607165,0.00003764786,0.00003526185],"category_scores_gemma":[0.0008023994,0.00007603283,0.00007999559,0.0000515564,0.00008562172,0.000008144217,0.00009822407,0.0001271267,0.000002214651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001779994,"about_ca_system_score_gemma":0.00007234001,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002332709,"about_ca_topic_score_gemma":0.000005040832,"domain_scores_codex":[0.9986665,0.00050322,0.0002232646,0.0002971562,0.0001367256,0.0001731489],"domain_scores_gemma":[0.9989677,0.0001112983,0.0002474971,0.0005889714,0.00003568078,0.00004884227],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2358281,0.0006442915,0.002160078,0.00004096191,0.0007498585,0.00008287605,0.002053417,0.00190827,0.4080808,0.001520557,0.193694,0.1532369],"study_design_scores_gemma":[0.02736185,0.0004921543,0.2595199,0.00001752553,0.000141434,0.00001097488,0.0006989614,0.0001921981,0.02113008,0.01111087,0.6788929,0.0004311737],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916649,0.00140955,0.0001077939,0.003691439,0.0004054497,0.0008274813,0.001800552,0.00002031437,0.00007252661],"genre_scores_gemma":[0.9944089,0.000537137,0.0000661521,0.001256139,0.002352028,0.0003590831,0.000744805,0.00002064872,0.0002550818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4851989,"threshold_uncertainty_score":0.3554609,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04230221700299876,"score_gpt":0.3244452588349456,"score_spread":0.2821430418319469,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}